296 related articles for article (PubMed ID: 31713445)
21. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
22. Tafamidis Treatment Decreases
Yu AL; Chen YC; Tsai CH; Chao CC; Su MY; Juang JJ; Lee MJ; Hsieh ST; Cheng MF; Lin YH
JACC Cardiovasc Imaging; 2023 Jun; 16(6):866-867. PubMed ID: 36881423
[No Abstract] [Full Text] [Related]
23. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis.
Dyck PJB; Coelho T; Waddington Cruz M; Brannagan TH; Khella S; Karam C; Berk JL; Polydefkis MJ; Kincaid JC; Wiesman JF; Litchy WJ; Mauermann ML; Ackermann EJ; Baker BF; Jung SW; Guthrie S; Pollock M; Dyck PJ
Muscle Nerve; 2020 Oct; 62(4):509-515. PubMed ID: 32654156
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
[TBL] [Abstract][Full Text] [Related]
25. A case of severe increase of liver enzymes in a ATTRv patient after one year of inotersen treatment.
Severi D; Palumbo G; Spina E; Iovino A; Nolano M; Manganelli F; Tozza S
Neurol Sci; 2023 Apr; 44(4):1419-1422. PubMed ID: 36576645
[TBL] [Abstract][Full Text] [Related]
26. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
27. Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy.
Capustin M; Frishman WH
Cardiol Rev; 2021 Sep-Oct 01; 29(5):263-273. PubMed ID: 34397539
[TBL] [Abstract][Full Text] [Related]
28. mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.
Dyck PJB; Kincaid JC; Wiesman JF; Polydefkis M; Litchy WJ; Mauermann ML; Ackermann EJ; Guthrie S; Pollock M; Jung SW; Baker BF; Dyck PJ
Muscle Nerve; 2020 Oct; 62(4):502-508. PubMed ID: 32654212
[TBL] [Abstract][Full Text] [Related]
29. The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.
Yarlas A; Lovley A; Brown D; Vera-Llonch M; Khella S; Karam C
BMC Neurol; 2023 Mar; 23(1):108. PubMed ID: 36932361
[TBL] [Abstract][Full Text] [Related]
30. Inotersen: First Global Approval.
Keam SJ
Drugs; 2018 Sep; 78(13):1371-1376. PubMed ID: 30120737
[TBL] [Abstract][Full Text] [Related]
31. Transthyretin Stabilizer Is Associated With Expanding Apical Sparing Area and Improving Global Cardiac Function in a Patient With Wild-Type Cardiac Amyloidosis.
Kato TS; Ikeda N; Maurer MS; Ando Y; Tanno K
Circ J; 2019 Feb; 83(3):690. PubMed ID: 30185690
[No Abstract] [Full Text] [Related]
32. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
33. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
[TBL] [Abstract][Full Text] [Related]
34. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
[TBL] [Abstract][Full Text] [Related]
35. Inotersen treatment for ATTR amyloidosis.
Benson MD
Amyloid; 2019; 26(sup1):27-28. PubMed ID: 31343345
[No Abstract] [Full Text] [Related]
36. Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival.
Tubben A; Nienhuis HLA; van der Meer P
Eur J Heart Fail; 2023 Nov; 25(11):2065-2066. PubMed ID: 37792736
[No Abstract] [Full Text] [Related]
37. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Lane T; Fontana M; Martinez-Naharro A; Quarta CC; Whelan CJ; Petrie A; Rowczenio DM; Gilbertson JA; Hutt DF; Rezk T; Strehina SG; Caringal-Galima J; Manwani R; Sharpley FA; Wechalekar AD; Lachmann HJ; Mahmood S; Sachchithanantham S; Drage EPS; Jenner HD; McDonald R; Bertolli O; Calleja A; Hawkins PN; Gillmore JD
Circulation; 2019 Jul; 140(1):16-26. PubMed ID: 31109193
[TBL] [Abstract][Full Text] [Related]
38. Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
Karam C; Brown D; Yang M; Done N; Zhu JJ; Greatsinger A; Bozas A; Vera-Llonch M; Signorovitch J
Muscle Nerve; 2022 Oct; 66(4):438-446. PubMed ID: 35799473
[TBL] [Abstract][Full Text] [Related]
39. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
40. Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations.
Marques N; Azevedo O; Almeida AR; Bento D; Cruz I; Correia E; Lourenço C; Lopes LR
J Am Heart Assoc; 2020 Oct; 9(19):e016614. PubMed ID: 32969287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
